TTAX03 / BioTissue - LARVOL DELTA

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: BioTissue Holdings, Inc | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Jan 2026

Enrollment closed • Trial primary completion date • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Completed | Sponsor: BioTissue Holdings, Inc | Active, not recruiting ➔ Completed

Trial completion • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: BioTissue Holdings, Inc | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology

TTAX03 for the Treatment of Lumbosacral Facet Joint Pain (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: BioTissue Holdings, Inc | N=36 ➔ 0 | Trial completion date: Nov 2025 ➔ Mar 2025 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial completion date • Trial withdrawal • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: BioTissue Holdings, Inc

New P2 trial • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: BioTissue Holdings, Inc | Trial primary completion date: Jul 2024 ➔ Mar 2025

Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Tissue Tech Inc. | Completed ➔ Active, not recruiting | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Jul 2024

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Completed | Sponsor: Tissue Tech Inc. | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Mar 2024 | Trial primary completion date: Aug 2024 ➔ Mar 2024

Trial completion • Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

TTAX03 for the Treatment of Lumbosacral Facet Joint Pain (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Tissue Tech Inc.

New P1 trial • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Tissue Tech Inc.

Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Tissue Tech Inc. | Trial completion date: Nov 2023 ➔ Aug 2024 | Trial primary completion date: Jan 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Tissue Tech Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: Tissue Tech Inc.

New P2 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain (PRNewswire) - "Amniox Medical...announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from Osteoarthritis (OA). This Phase 1 randomized, double-blinded, placebo-controlled, dose-finding study will include a one-year follow-up to assess TTAX03's long-term safety and potential lasting benefit."

IND • New P1 trial • Osteoarthritis • Pain